SGT-25 or 5F-CUMYL-PINACA, as it's sometimes known, is also sometimes sold in e-cigarette form as C-Liquid is an indazole-3-carboxamide based synthetic cannabinoid. 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB1, having an EC50 of <0.1 nM for human CB1 receptors and 0.37nM for human CB2 receptors. In more recent assays using different techniques, 5F-CUMYL-PINACA was variously found to have an EC50 of 0.43nM at CB1 and 11.3nM at CB2, suggesting a somewhat higher CB1 selectivity of 26x, or alternatively 15.1nM at CB1 and 34.8nM at CB2 with only 2.3x selectivity, however these figures cannot be directly compared due to the different assay techniques used in each case.
SGT-25 Cannabinoid is sold for research purposes only and is not be utilized for any other purposes, including, but not limited to, in vivo diagnostic purposes, in foods, in drugs, in medicinal devices, and/or cosmetics for humans and/or animals.
Prior to ordering, please make certain that you are properly equipped for research chemicals and that your work area is well-ventilated.
You must be 18 or more years old to order this product.
SGT-25 Cannabinoid is legal in our country of origin. It is your responsibility to know and abide by the laws in your country/county/region/state/city. We accept no responsibility for any actions or consequences that are a result of your decision to order.
Why Buy SGT-25 Cannabinoid From Us?
- We are a long established and trusted supplier of Research Chemicals
- 24 hour Live Chat...ask any questions, if you're unsure of anything at all
- Various Payment options to suit your needs
- We offer Same-Day shiping, provided you order before 4pm CET
- Our customers leave genuine reviews which allow you to buy with confidence
Looking for Wholesale?
Click here to contact us about Wholesale pricing for SGT-25 Cannabinoid
Write a reviewYour Name:
Your Review: Note: HTML is not translated!
Rating: Bad Good
Enter the code in the box below:
From: Alejandro Norte d...
From: Gerald LE PLES...